Co-Authors
This is a "connection" page, showing publications co-authored by Sue Leurgans and Elliott Mufson.
Connection Strength
0.621
-
Inability of plasma and urine F2A-isoprostane levels to differentiate mild cognitive impairment from Alzheimer's disease. Neurodegener Dis. 2010; 7(1-3):139-42.
Score: 0.337
-
Hippocampal proNGF signaling pathways and ?-amyloid levels in mild cognitive impairment and Alzheimer disease. J Neuropathol Exp Neurol. 2012 Nov; 71(11):1018-29.
Score: 0.101
-
Preservation of brain nerve growth factor in mild cognitive impairment and Alzheimer disease. Arch Neurol. 2003 Aug; 60(8):1143-8.
Score: 0.053
-
Loss of basal forebrain P75(NTR) immunoreactivity in subjects with mild cognitive impairment and Alzheimer's disease. J Comp Neurol. 2002 Feb 04; 443(2):136-53.
Score: 0.048
-
Cortical pyroglutamate amyloid-? levels and cognitive decline in Alzheimer's disease. Neurobiol Aging. 2015 Jan; 36(1):12-9.
Score: 0.028
-
MRI-based volumetric measurement of the substantia innominata in amnestic MCI and mild AD. Neurobiol Aging. 2011 Oct; 32(10):1756-64.
Score: 0.021
-
Cortical biochemistry in MCI and Alzheimer disease: lack of correlation with clinical diagnosis. Neurology. 2007 Mar 06; 68(10):757-63.
Score: 0.017
-
Effects of estrogen replacement therapy on cholinergic basal forebrain neurons and cortical cholinergic innervation in young and aged ovariectomized rhesus monkeys. J Comp Neurol. 2004 Apr 26; 472(2):193-207.
Score: 0.014